DRAFT AGENDA

Monday, October 27, 2008
7:15 a.m. – 8:00 a.m. Registration and Continental Breakfast
   
Introductions and Overviews
8:00 a.m. – 8:15 a.m. Welcome and Workshop Introduction
8:15 a.m. – 9:15 a.m.

Overview:  Iron Overload as a Global Health Burden
David Weatherall, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, UK
   
Mechanisms Underlying Iron Overload
9:15 a.m. – 9:45 a.m. Diverse Mechanisms of Hepcidin Deficiency or Hepcidin Resistance in Hereditary Hemochromatosis
Tomas Ganz, Geffen School of Medicine, UCLA, Los Angeles, CA
9:45 a.m. – 10:15 a.m. The Molecular Basis and Consequences of Hepcidin Mediated Ferroportin Downregulation
Ivana DeDomenico, University of Utah Sch. of Medicine, Salt Lake City, UT
10:15 a.m. – 10:30 a.m. Break
10:30 a.m. – 11:00 a.m. Multiple Roles of Hemojuvelin in Iron Deficiency and Overload
Clara Camaschella, Università Vita-Salute San Raffaele, Milano, Italy
11:00 a.m. – 11:30 a.m. Hereditary Hemochromatosis:  An Eclectic Family of Dysfunctional Proteins
Carolyn Enns, Oregon Health & Science University, Portland, OR
11:30 a.m. – 12:00 p.m. Regulatory Mechanisms in Hereditary Hemochromatosis
Martina Muckenthaler, University of Heidelberg, Heidelberg, Germany
12:00 p.m. – 12:30 p.m. Enteric Regulation of Iron Absorption
Richard Ajioka, University of Utah School of Medicine, Salt Lake City, UT
12:30 p.m. – 2:00 p.m. Lunch
2:00 p.m. – 2:30 p.m. Role of TMPRSS6, a Type II Transmembrane Serine Protease, in the Control of Systemic Iron Homeostasis in Humans
Karin Finberg, Duke University Medical Center, Durham, NC
2:30 p.m. – 3:00 p.m. Pathological Iron Overload Due to Ineffective Erythropoiesis
Jeff Miller, Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), Bethesda, MD
3:00 p.m. – 3:30 p.m. Differing Patterns of Transfusional Iron Overload in Thalassemia and Sickle Cell Disease:  Clinical Observations and Possible Mechanisms
Elliott Vichinsky, Children’s Hospital Oakland Research Institute, Oakland, CA
John Porter, Haematology Division, University College, London, UK
3:30 p.m. – 3:45 p.m. Break
3:45 p.m. – 4:15 p.m. Pathophysiology of Iron-Related Toxicty
Kris Kowdley, Center for Liver Disease, Virginia Mason Medical Center, Seattle, WA
4:15 p.m. – 4:45 p.m. Hepcidin as a Novel Diagnostic Test:  Analysis and Clinical Applicability  
Dorine Swinkels, Radboud University Medical Center, Nijmegen, Netherlands
4:45 p.m. – 5:15 p.m. Serum Hepcidin Immunoassay
Elizabeta Nemeth, University of California – Los Angeles, Department of Medicine, Los Angeles, CA
   
Presentations from Poster Presenters
5:15 p.m. – 6:15 p.m. Selected Concise Presentations from Abstracts
6:15 p.m. – 7:00 p.m. Poster Presentations (followed by dinner)
   

Tuesday, October 28, 2008
7:15 a.m. – 8:00 a.m. Registration and Continental Breakfast
   
Measuremen of Iron Overload: Degree, Distribution, and Duration
8:00 a.m. – 8:30 a.m.

Imaging Organ Iron: Influence of Particle Size and Distribution
John Wood, Children’s Hospital, Los Angeles, University of Southern California, Los Angeles, CA
8:30 a.m. – 9:00 a.m. Myocardial Siderosis Assessment by T2*
Dudley Pennell, Imperial College, Royal Brompton Hospital, London
9:00 a.m. – 9:30 a.m. Tissue Iron Measurement Using Quantitative R2 Relaxometry – Applications in Hereditary Haemochromatosis and Alzheimer’s Disease
Michael House, School of Physics, University of West Australia, Crawley, Australia
9:30 a.m. – 10:00 a.m. Separate MRI Quantification of Dispersed (Ferritin-like) and Aggregated (Hemosiderin-like) Storage Iron
Jens Jensen, Center for Biomedical Imaging, Department of Radiology, New York University, New York, NY
10:00 a.m. – 10:30 a.m. Break
10:30 a.m. – 11:00 a.m. Non-Invasive Assessment of Tissue Iron:  The Meaning of the Measurements
Gary Brittenham, Columbia University, Children's Hospital of New York, New York, NY
   
Management of Iron Overload: Current Methods and Novel Approaches
11:00 a.m. – 11:30 a.m. Should the Availability of New Diagnostic Methods and New Chelation Regimes Change Our Treatment Goals for Transfusional Iron Overload?
John Porter, Haematology, University College, London, UK
11:30 a.m. – 12:00 p.m.  Tailoring Iron Chelation to the Needs of the Patients
Renzo Galanello, University di Cagliari, Ospedale Regionale

Microcitemie, Cagliari, Italy
12:00 p.m. – 12:30 p.m. The Role of Transfusion Therapy in the Management of Iron Overload
Alan Cohen, Children's Hospital of Pennsylvania, University of Pennslyvania, Philadelphia, PA
12:30 p.m. – 2:00 p.m. Lunch
2:00 p.m. – 2:30 p.m. Disorders Associated with Iron Misdistribution:  The Therapeutic Potential for Siderophores
Z. Ioav Cabantchik, Life Sciences Institute, Hebrew University, Jerusalem, Israel
2:30 p.m. – 3:00 p.m. The Desferrithiocin Pharmacophore:  A Structure Activity Study
Ray Bergeron, University of Florida, Gainesville, FL
3:00 p.m. – 3:30 p.m.

Going for the Iron:  Targeting Chelators to Ferritin
Elizabeth Theil, Children’s Hosp Oakland Research Institute, Oakland, CA
   
Summary Commentary
3:30 p.m. – 4:00 p.m. Nancy Andrews, Duke University Medical Center, Durham, NC
Jerry Kaplan, University of Utah School of Medicine, Salt Lake City, UT
4:00 p.m. Workshop adjourns
   

 



 
NIDDK National Institutes of Health U.S. Department of Health & Human Services